8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Apr 13, 2026·SEC
Material company update
Mar 13, 2026·SEC
Xenon Pharmaceuticals Inc.(XENE)Earnings, Financials & Key Ratios
XENE•NASDAQ
Price updated Jun 19, 2026
AboutXenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.Show more
- Revenue$8M
- EBITDA-$371M-33.9%
- Net Income-$346M-47.6%
- EPS (Diluted)-4.36-44.9%
- Gross Margin66.09%
- EBITDA Margin-4940.36%
- Operating Margin-4974.27%
- Net Margin-4612.13%
- ROE-51.76%-85.8%
XENE Key Insights
Xenon Pharmaceuticals Inc. (XENE) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Profits declining 64.4% over 5 years
- ✗Negative free cash flow
- ✗Sales declining 25.3% over 5 years
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when XENE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
XENE Price & Volume
Xenon Pharmaceuticals Inc. (XENE) stock price & volume — 10-year historical chart
Loading chart...
XENE Growth Metrics
Xenon Pharmaceuticals Inc. (XENE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-7.05%
5 Years-25.26%
3 Years-7.36%
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-52.38%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-45.51%
Return on Capital
10 Years-35.34%
5 Years-28.79%
3 Years-34.11%
Last Year-43.83%
XENE Recent Earnings
Xenon Pharmaceuticals Inc. (XENE) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 2/12 qtrs (100%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$1.17+0.0%
$1.17
Rev
—
$1M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$1.31-9.2%
$1.20
Rev
—
$178,571
Q4 2025
Nov 3, 2025Metric
Actual
Est
EPS
$1.15+0.9%
$1.16
Rev
—
—
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$1.07-3.9%
$1.03
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $1.17vs $1.17+0.0% | —vs $1M |
| Q1 2026 | Feb 26, 2026 | $1.31vs $1.20-9.2% | —vs $178,571 |
| Q4 2025 | Nov 3, 2025 | $1.15vs $1.16+0.9% | — |
| Q3 2025 | Aug 11, 2025 | $1.07vs $1.03-3.9% | — |
Based on last 12 quarters of dataView full earnings history →
XENE Peer Comparison
Xenon Pharmaceuticals Inc. (XENE) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 PTCT | 6.55B | 78.98 | 10.15 | 114.51% | -22.58% | |||
 ARVN | 494.88M | 7.67 | -5.99 | -0.3% | -247.54% | -44.39% | 0.02 | |
 OVID | 299.38M | 2.27 | -9.46 | 11.81% | -339.33% | -22.51% | 0.10 | |
 LGND | 5.51B | 274.88 | 44.84 | 60.4% | 55.95% | 16.19% | 0.44 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 ABBV | 383.17B | 216.63 | 91.41 | 8.57% | 6.91% | 62.15% |
Compare XENE vs Peers
Xenon Pharmaceuticals Inc. (XENE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
XENE Income Statement
Xenon Pharmaceuticals Inc. (XENE) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 311K | 0 | 6.83M | 32.17M | 18.44M | 9.43M | 0 | 0 | 7.5M | 0 |
Revenue Growth % | -82.75% | -100% | - | 371.02% | -42.68% | -48.83% | -100% | - | - | -100% |
Cost of Goods Sold | 25.57M | 6M | 0 | 0 | 0 | 0 | 167.51M | 2.56M | 2.54M | 78.3M |
COGS % of Revenue | 8222.83% | - | - | - | - | - | - | - | 33.91% | - |
Gross Profit | -25.26M▲ 0% | -6M▲ 76.2% | 6.83M▲ 213.8% | 32.17M▲ 371.0% | 18.44M▼ 42.7% | 9.43M▼ 48.8% | -167.51M▼ 1875.6% | -2.56M▲ 98.5% | 4.96M▲ 293.6% | -78.3M▲ 0% |
Gross Margin % | -8122.83% | - | 100% | 100% | 100% | 100% | - | - | 66.09% | - |
Gross Profit Growth % | -3766.47% | 76.25% | 213.82% | 371.02% | -42.68% | -48.83% | -1875.62% | 98.47% | 293.63% | - |
Operating Expenses | 32.89M | 32.02M | 49.65M | 63.47M | 97.43M | 138.58M | 46.54M | 276.74M | 378.03M | 334.36M |
OpEx % of Revenue | 10574.28% | - | 727.02% | 197.31% | 528.45% | 1468.91% | - | - | 5040.36% | - |
Selling, General & Admin | 7.31M | 8.38M | 10.8M | 12.94M | 21.97M | 32.81M | 46.54M | 68.9M | 79.63M | 84.41M |
SG&A % of Revenue | 2351.45% | - | 158.19% | 40.24% | 119.15% | 347.78% | - | - | 1061.76% | - |
Research & Development | 25.57M | 23.63M | 38.84M | 50.52M | 75.46M | 105.77M | 167.51M | 210.39M | 300.94M | 328.25M |
R&D % of Revenue | 8222.83% | - | 568.82% | 157.07% | 409.3% | 1121.13% | - | - | 4012.51% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | -167.51M | -2.56M | -2.54M | -2.24M |
Operating Income | -32.58M▲ 0% | -38.02M▼ 16.7% | -42.82M▼ 12.6% | -31.3M▲ 26.9% | -78.99M▼ 152.4% | -129.14M▼ 63.5% | -214.05M▼ 65.7% | -279.3M▼ 30.5% | -373.07M▼ 33.6% | -412.66M▲ 0% |
Operating Margin % | -10474.28% | - | -627.02% | -97.31% | -428.45% | -1368.91% | - | - | -4974.27% | - |
Operating Income Growth % | -31.26% | -16.7% | -12.63% | 26.9% | -152.37% | -63.49% | -65.75% | -30.48% | -33.57% | - |
EBITDA | -31.93M | -37.43M | -42.39M | -30.66M | -78.09M | -127.74M | -210.51M | -276.74M | -370.53M | -410.19M |
EBITDA Margin % | -10265.59% | - | -620.74% | -95.31% | -423.53% | -1354.02% | - | - | -4940.36% | - |
EBITDA Growth % | -33.29% | -17.24% | -13.25% | 27.68% | -154.71% | -63.58% | -64.8% | -31.46% | -33.89% | -41.27% |
D&A (Non-Cash Add-back) | 649K | 586K | 429K | 644K | 906K | 1.41M | 3.54M | 2.56M | 2.54M | 2.47M |
EBIT | -30.7M | -33.13M | -40.18M | -28.61M | -78.99M | -129.14M | -214.05M | -238.42M | -344.89M | -401.5M |
Net Interest Income | 477K | -178K | 919K | 1.79M | 466K | 8.71M | 27.62M | 41.94M | 26.83M | 26.52M |
Interest Income | 477K | 1.22M | 2.35M | 2.28M | 466K | 8.71M | 27.62M | 41.94M | 26.83M | 26.52M |
Interest Expense | 0 | 1.39M | 1.43M | 484K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 1.87M | 6.4M | 1.2M | 2.21M | 105K | 3.89M | 31.37M | 40.88M | 28.18M | 27.51M |
Pretax Income | -30.7M▲ 0% | -34.5M▼ 12.4% | -41.62M▼ 20.6% | -29.09M▲ 30.1% | -78.89M▼ 171.1% | -125.25M▼ 58.8% | -182.69M▼ 45.9% | -238.42M▼ 30.5% | -344.89M▼ 44.7% | -385.15M▲ 0% |
Pretax Margin % | -9872.67% | - | -609.43% | -90.45% | -427.88% | -1327.7% | - | - | -4598.59% | - |
Income Tax | 0 | 4.91M | -23K | -257K | -6K | 118K | -292K | -4.09M | 1.02M | -1.98M |
Effective Tax Rate % | 0% | -14.24% | 0.06% | 0.88% | 0.01% | -0.09% | 0.16% | 1.72% | -0.29% | 0.51% |
Net Income | -30.7M▲ 0% | -34.5M▼ 12.4% | -41.59M▼ 20.6% | -28.84M▲ 30.7% | -78.88M▼ 173.5% | -125.37M▼ 58.9% | -182.39M▼ 45.5% | -234.33M▼ 28.5% | -345.91M▼ 47.6% | -383.17M▲ 0% |
Net Margin % | -9872.67% | - | -609.09% | -89.65% | -427.85% | -1328.95% | - | - | -4612.13% | - |
Net Income Growth % | -33.51% | -12.35% | -20.58% | 30.67% | -173.54% | -58.94% | -45.48% | -28.48% | -47.62% | -52.38% |
Net Income (Continuing) | -30.7M | -34.5M | -41.59M | -28.84M | -78.88M | -125.37M | -182.39M | -234.33M | -345.91M | -383.17M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.71▲ 0% | -1.78▼ 4.1% | -1.54▲ 13.5% | -0.83▲ 46.1% | -1.77▼ 113.3% | -2.06▼ 16.4% | -2.73▼ 32.5% | -3.01▼ 10.3% | -4.36▼ 44.9% | -4.39▲ 0% |
EPS Growth % | -15.54% | -4.09% | 13.48% | 46.1% | -113.25% | -16.38% | -32.52% | -10.26% | -44.85% | -45.51% |
EPS (Basic) | -1.71 | -1.78 | -1.54 | -0.83 | -1.77 | -2.06 | -2.73 | -3.01 | -4.36 | - |
Diluted Shares Outstanding | 18M | 19.43M | 25.94M | 34.54M | 43.63M | 60.54M | 66.89M | 77.89M | 79.25M | 87.35M |
Basic Shares Outstanding | 17.99M | 19.43M | 25.94M | 34.54M | 43.63M | 60.54M | 66.89M | 77.89M | 79.25M | 87.35M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
XENE Balance Sheet
Xenon Pharmaceuticals Inc. (XENE) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 44.82M | 121.44M | 144.87M | 181.78M | 559.02M | 600.3M | 644.96M | 635.26M | 560.65M | 1.11B |
Cash & Short-Term Investments | 43.67M | 119.31M | 141.36M | 177M | 551.77M | 592.09M | 638.08M | 626.9M | 548.89M | 1.09B |
Cash Only | 20.49M | 67.75M | 24.75M | 45.01M | 175.69M | 57.24M | 148.64M | 142.71M | 199.16M | 545.87M |
Short-Term Investments | 23.18M | 51.55M | 116.6M | 131.99M | 376.09M | 534.85M | 489.44M | 484.19M | 349.72M | 548.88M |
Accounts Receivable | 438K | 151K | 813K | 1.82M | 2.77M | 986K | 874K | 1.47M | 1.37M | 1.17M |
Days Sales Outstanding | 514.05 | - | 43.45 | 20.67 | 54.74 | 38.15 | - | - | 66.72 | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 7.22M | 6.01M | 6.89M | 10.39M | 10.72M |
Total Non-Current Assets | 1.3M | 991K | 2.83M | 7.4M | 12.99M | 153.85M | 319.84M | 162.88M | 421.02M | 280.18M |
Property, Plant & Equipment | 1.07M | 991K | 2.59M | 6.88M | 12.52M | 16.91M | 18.85M | 18.22M | 15.35M | 0 |
Fixed Asset Turnover | 0.29x | - | 2.63x | 4.68x | 1.47x | 0.56x | - | - | 0.49x | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 128.68M | 292.79M | 127.5M | 37.15M | 512.31M |
Other Non-Current Assets | 230K | -105K | 0 | 0 | 0 | 7.75M | 7.4M | 7.5M | 7.15M | 35.3M |
Total Assets | 46.12M▲ 0% | 122.43M▲ 165.4% | 147.7M▲ 20.6% | 189.19M▲ 28.1% | 572.01M▲ 202.4% | 754.15M▲ 31.8% | 964.8M▲ 27.9% | 798.14M▼ 17.3% | 981.67M▲ 23.0% | 1.39B▲ 0% |
Asset Turnover | 0.01x | - | 0.05x | 0.17x | 0.03x | 0.01x | - | - | 0.01x | 0.00x |
Asset Growth % | -31.66% | 165.45% | 20.64% | 28.09% | 202.35% | 31.84% | 27.93% | -17.27% | 22.99% | 58.57% |
Total Current Liabilities | 4.08M | 4.12M | 43.38M | 14.78M | 14.32M | 22.7M | 27.27M | 35.59M | 41.79M | 39.81M |
Accounts Payable | 1.25M | 665K | 2.47M | 3.04M | 3.82M | 8.49M | 8.6M | 5.07M | 3.88M | 5.75M |
Days Payables Outstanding | 17.88 | 40.45 | - | - | - | - | 18.73 | 722.87 | 557.62 | 22.11 |
Short-Term Debt | 700K | 0 | 4.65M | 0 | 0 | 0 | 0 | 0 | 1.53M | 0 |
Deferred Revenue (Current) | 0 | -15.01M | 29.74M | 3.64M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 44K | 1.73M | 3.45M | 2.86M | 5.94M | 5.82M | 347K | 9.93M | 21.6M | 32.24M |
Current Ratio | 10.98x | 29.48x | 3.34x | 12.30x | 39.03x | 26.44x | 23.65x | 17.85x | 13.42x | 27.79x |
Quick Ratio | 10.98x | 29.48x | 3.34x | 12.30x | 39.03x | 26.44x | 23.65x | 17.85x | 13.42x | 27.79x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 6.1M | 15.01M | 12.34M | 3.05M | 7.65M | 9.95M | 9.6M | 7.65M | 358.12M | 9.18M |
Long-Term Debt | 6.1M | 15.01M | 10.89M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 743K | 3.05M | 7.65M | 9.95M | 9.6M | 7.65M | 6.41M | 26.43M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 348.51M | 348.51M |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.2M | 3.25M |
Total Liabilities | 10.19M | 19.13M | 55.72M | 17.83M | 21.97M | 32.65M | 36.88M | 43.24M | 399.91M | 48.99M |
Total Debt | 6.8M | 15.01M | 16.45M | 3.31M | 8.26M | 10.44M | 10.9M | 9.02M | 7.94M | 7.49M |
Net Debt | -13.68M | -52.74M | -8.3M | -41.69M | -167.43M | -46.81M | -137.74M | -133.7M | -191.22M | -538.38M |
Debt / Equity | 0.19x | 0.15x | 0.18x | 0.02x | 0.02x | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.02x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 1.31x |
Interest Coverage | - | -23.76x | -28.02x | -59.11x | - | - | - | - | - | - |
Total Equity | 35.93M▲ 0% | 103.3M▲ 187.5% | 91.98M▼ 11.0% | 171.35M▲ 86.3% | 550.03M▲ 221.0% | 721.5M▲ 31.2% | 927.92M▲ 28.6% | 754.9M▼ 18.6% | 581.76M▼ 22.9% | 1.34B▲ 0% |
Equity Growth % | -43.77% | 187.46% | -10.96% | 86.3% | 220.99% | 31.17% | 28.61% | -18.65% | -22.94% | 12.35% |
Book Value per Share | 2.00 | 5.32 | 3.55 | 4.96 | 12.61 | 11.92 | 13.87 | 9.69 | 7.34 | 15.32 |
Total Shareholders' Equity | 35.93M | 103.3M | 91.98M | 171.35M | 550.03M | 721.5M | 927.92M | 754.9M | 581.76M | 1.34B |
Common Stock | 173.84M | 265.92M | 294.24M | 397.75M | 783.17M | 1.07B | 1.44B | 1.46B | 1.6B | 2.42B |
Retained Earnings | -173.39M | -207.88M | -249.66M | -278.49M | -357.37M | -482.75M | -665.14M | -899.47M | -1.25B | -1.35B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -990K | -990K | -990K | -990K | -990K | -3M | -77K | -1.61M | 335K | -1.21M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
XENE Cash Flow Statement
Xenon Pharmaceuticals Inc. (XENE) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -28.73M | -34.72M | -4.63M | -48.12M | -69.5M | -98.43M | -145.33M | -181.39M | -279.12M | -306.36M |
Operating CF Margin % | -9236.66% | - | -67.83% | -149.61% | -376.97% | -1043.35% | - | - | -3721.57% | - |
Operating CF Growth % | -46.81% | -20.88% | 86.66% | -938.95% | -44.42% | -41.62% | -47.64% | -24.81% | -53.88% | -235.04% |
Net Income | -30.7M | -34.5M | -41.59M | -28.84M | -78.88M | -125.37M | -182.39M | -234.33M | -345.91M | -383.17M |
Depreciation & Amortization | 649K | 586K | 429K | 644K | 906K | 1.62M | 3.54M | 2.56M | 2.54M | 2.47M |
Stock-Based Compensation | 2.24M | 2.63M | 2.92M | 5.68M | 10.02M | 20.38M | 32.37M | 50.72M | 53.71M | 58.43M |
Deferred Taxes | -1.47M | 646K | -133K | -285K | 58K | -44K | -292K | -8.86M | -3.2M | -837K |
Other Non-Cash Items | 11K | -4.11M | 223K | 766K | 1.05M | 5.66M | -4.19M | 2.81M | 9.38M | 8.72M |
Working Capital Changes | 556K | 30K | 33.52M | -26.09M | -2.65M | -676K | 5.63M | 5.71M | 4.36M | 8.02M |
Change in Receivables | -232K | 175K | -653K | -1.03M | -459K | 1.76M | 130K | -614K | 104K | 7.48M |
Change in Inventory | 613K | -783K | -4.54M | -2.02M | -2.97M | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -3K | 783K | 4.54M | 2.02M | 2.97M | 8.06M | 3.93M | 8.53M | 5.51M | 2.24M |
Cash from Investing | 24.29M | -28.99M | -66.29M | -16.82M | -246.77M | -296M | -117.17M | 165M | 218M | -223.79M |
Capital Expenditures | -315K | -507K | -1.24M | -2.64M | -2.05M | -2.89M | -5.62M | -3.08M | -799K | -889K |
CapEx % of Revenue | 101.29% | - | 18.16% | 8.2% | 11.12% | 30.68% | - | - | 10.65% | - |
Acquisitions | -52.62M | -48.52M | -75.44M | -214.71M | -144.75M | 296M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 52.62M | 48.52M | 75.44M | 214.71M | 144.75M | -296M | 0 | 0 | 0 | -213.11M |
Cash from Financing | 7.07M | 111.59M | 27.52M | 85.8M | 447.54M | 278.47M | 353.52M | 12.13M | 117.11M | 958.98M |
Debt Issued (Net) | 6.89M | 8.45M | 0 | -16.74M | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 102.85M | 27.4M | 102.46M | 447.28M | 277.77M | 353.49M | 12.08M | 117.11M | 959.22M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 177K | 288K | 122K | 82K | 260K | 705K | 35K | 47K | 0 | -247.43K |
Net Change in Cash | 3.39M▲ 0% | 47.27M▲ 1293.9% | -43M▼ 191.0% | 20.25M▲ 147.1% | 130.68M▲ 545.2% | -118.45M▼ 190.6% | 91.4M▲ 177.2% | -5.93M▼ 106.5% | 56.45M▲ 1051.8% | 429.21M▲ 0% |
Free Cash Flow | -29.04M▲ 0% | -35.23M▼ 21.3% | -5.87M▲ 83.3% | -50.76M▼ 764.5% | -71.55M▼ 41.0% | -101.32M▼ 41.6% | -150.94M▼ 49.0% | -184.46M▼ 22.2% | -279.92M▼ 51.7% | -307.25M▲ 0% |
FCF Margin % | -9337.94% | - | -85.99% | -157.81% | -388.09% | -1074.03% | - | - | -3732.23% | - |
FCF Growth % | -46.33% | -21.31% | 83.33% | -764.46% | -40.96% | -41.61% | -48.97% | -22.21% | -51.75% | -52.63% |
FCF per Share | -1.61 | -1.81 | -0.23 | -1.47 | -1.64 | -1.67 | -2.26 | -2.37 | -3.53 | -3.52 |
FCF Conversion (FCF/Net Income) | 0.94x | 1.01x | 0.11x | 1.67x | 0.88x | 0.79x | 0.80x | 0.77x | 0.81x | 0.80x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.65M |
XENE Key Ratios
Xenon Pharmaceuticals Inc. (XENE) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -61.51% | -49.55% | -42.6% | -21.9% | -21.87% | -19.72% | -22.12% | -27.85% | -51.76% | -49.23% |
Return on Invested Capital (ROIC) | -70.76% | -78.32% | -47.85% | -22.01% | -23.13% | -18.32% | -21.92% | -29.68% | -55.31% | -57.3% |
Gross Margin | -8122.83% | - | 100% | 100% | 100% | 100% | - | - | 66.09% | - |
Net Margin | -9872.67% | - | -609.09% | -89.65% | -427.85% | -1328.95% | - | - | -4612.13% | - |
Debt / Equity | 0.19x | 0.15x | 0.18x | 0.02x | 0.02x | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x |
Interest Coverage | - | -23.76x | -28.02x | -59.11x | - | - | - | - | - | - |
FCF Conversion | 0.94x | 1.01x | 0.11x | 1.67x | 0.88x | 0.79x | 0.80x | 0.77x | 0.81x | 0.80x |
Revenue Growth | -82.75% | -100% | - | 371.02% | -42.68% | -48.83% | -100% | - | - | -100% |
Related:XENE Dividend History·XENE Revenue History·XENE Price History·XENE P/E History·XENE Financial Ratios·XENE Institutional Holders
XENE SEC Filings & Documents
Xenon Pharmaceuticals Inc. (XENE) SEC filings — annual & quarterly reports (10-K, 10-Q)
XENE Frequently Asked Questions
Xenon Pharmaceuticals Inc. (XENE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Xenon Pharmaceuticals Inc. (XENE) reported $7.5M in revenue for fiscal year 2025. This represents a 48% decrease from $14.3M in 2012.
Xenon Pharmaceuticals Inc. (XENE) grew revenue by 0.0% over the past year. Growth has been modest.
Xenon Pharmaceuticals Inc. (XENE) reported a net loss of $383.2M for fiscal year 2025.
Dividend & Returns
Xenon Pharmaceuticals Inc. (XENE) has a return on equity (ROE) of -51.8%. Negative ROE indicates the company is unprofitable.
Xenon Pharmaceuticals Inc. (XENE) had negative free cash flow of $307.3M in fiscal year 2025, likely due to heavy capital investments.